Cadila Healthcare climbs after FIBP approval

The pharma company was reconsidered by the FIPB following the changes made by the government in foreign direct investment policy last month.

Cadila Healthcare climbed 1.9% to Rs.395 on BSE. FIPB approved proposals of Cadila Healthcare on Monday. The pharma company was reconsidered by the FIPB following the changes made by the government in foreign direct investment policy last month.

The scrip opened at Rs. 395.05 and has touched a high and low of Rs. 397 and Rs. 394.05 respectively. So far 329761(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 39695.62 crore.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.4 on 23-Oct-2015 and a 52 week low of Rs. 285.02 on 05-Feb-2015. Last one week high and low of the scrip stood at Rs. 403.4 and Rs. 386.7 respectively.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 15.08 % and 10.13 % respectively.

The stock is currently trading above its 50 DMA.